TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
An autopsy study of 230 people with Parkinson’s found higher rates of Alzheimer’s amyloid pathology in women, particularly among those with Parkinson’s disease dementia. Researchers found no sex difference in tau pathology or cognitive impairment, and say further research is needed before any treatment implications are known.
A study of 230 autopsy cases found that women with Parkinson’s disease had higher rates of Alzheimer’s amyloid pathology than men, with the difference particularly apparent among women who had Parkinson’s disease dementia. Published in the Journal of Parkinson’s Disease, the research adds evidence that the brain changes associated with different neurodegenerative diseases can overlap, but it does not show that amyloid causes dementia in women with Parkinson’s or that an Alzheimer’s treatment would help them.
Researchers examined autopsy cases from the Arizona Study of Aging and Neurodegenerative Disorders and the Brain and Body Donation Program. They compared Alzheimer’s-related pathology in the brains of people with Parkinson’s, focusing on differences between women and men. The study’s title describes a greater burden of Alzheimer’s co-pathology in women with Parkinson’s disease dementia.
The reported difference concerned amyloid pathology, which involves protein deposits associated with Alzheimer’s disease. The researchers did not find a corresponding difference between women and men in tau pathology or in levels of cognitive impairment. Those findings describe patterns in the examined autopsy cases; they do not establish that all women with Parkinson’s have more amyloid or that sex alone predicts an individual’s disease course.
Erika Driver-Dunckley, a Mayo Clinic movement-disorder neurologist and one of the study’s lead researchers, said the team was interested in the sex difference because mixed brain pathologies are commonly found at autopsy. The researchers said their results may help guide work on the relationship between Parkinson’s and Alzheimer’s, including studies of whether amyloid could be relevant to some patients with Parkinson’s disease dementia.
Why Amyloid Findings Matter in Parkinson’s
The findings matter because Parkinson’s dementia can involve more than one type of brain pathology. A person may receive a clinical diagnosis of Parkinson’s, while examination of the brain after death identifies changes associated with other neurodegenerative diseases as well. Better understanding of these overlaps could help researchers explain why cognitive outcomes differ among people with Parkinson’s and identify biological features worth investigating in future studies.
The results also raise a research question about anti-amyloid medicines, which are approved for certain patients diagnosed with Alzheimer’s disease. Driver-Dunckley said the findings suggest researchers could study whether such treatments might benefit a subset of people with Parkinson’s disease dementia who also have increased amyloid pathology. That is a possibility for investigation, not evidence that the medicines work for Parkinson’s dementia or that patients should take them for that purpose.
The absence of a reported sex difference in tau pathology or cognitive impairment also limits what can be inferred. The study identifies a difference in one pathology measure, but does not show that this difference leads to greater impairment or explains why a person develops dementia.
Products Worth Considering
Blueair Blue Pure 511i Max Air Purifier
BowFlex Results Series SelectTech Adjustable Dumbbells (Pair)
Fitbit Charge 6 Fitness Tracker – Obsidian/Black
As an affiliate, we earn on qualifying purchases.
Mixed Pathology in Parkinson’s Autopsies
The study addresses co-pathology: the presence of changes associated with multiple neurodegenerative diseases in the same brain. Driver-Dunckley said people may enter a brain donation program with one diagnosis, while autopsy can reveal additional pathology. The researchers described these mixed findings as common in their experience; what drew their attention in this study was the observed difference between women and men in amyloid pathology.
The report was published in the Journal of Parkinson’s Disease as “Greater burden of Alzheimer’s Co-pathology in women with Parkinson’s disease dementia.” The research drew on 230 autopsy cases from AZSAND and the Brain and Body Donation Program. Because the analysis concerns donated brains examined after death, it offers evidence about pathology in that sample, rather than a population-wide estimate of risk for every person living with Parkinson’s.
“In women, particularly those with Parkinson’s disease dementia, they had higher rates of Alzheimer’s amyloid pathology.”
— Erika Driver-Dunckley, Mayo Clinic movement-disorder neurologist and study lead researcher
Limits of the Autopsy Evidence
The available report does not provide enough detail to establish how large the difference was, how the cases were selected, or whether the result applies beyond the donated-brain sample. The finding is an association in autopsy cases, not proof that amyloid causes Parkinson’s disease dementia or that women with Parkinson’s will develop Alzheimer’s disease.
It is also unclear whether amyloid pathology affected cognitive symptoms in the participants. The researchers reported no sex difference in measured cognitive impairment, despite the difference in amyloid findings. The study does not establish why the pathology differed or whether the finding reflects other factors among the groups.
No treatment benefit was tested. The suggestion that anti-amyloid drugs might be studied in some patients with Parkinson’s disease dementia remains a research possibility, not a clinical recommendation. Further studies would need to assess which patients, if any, could benefit and whether treatment is safe and effective for them.
Research Needed Before Treatment Changes
The next step is further research to test whether the amyloid difference is replicated in other groups and to clarify how it relates to cognition and disease progression. Researchers would also need to determine whether amyloid measures can identify a meaningful subgroup of people with Parkinson’s disease dementia.
Any test of anti-amyloid treatment in Parkinson’s dementia would require dedicated clinical research. The study does not report a treatment trial or a change to current care. For now, its contribution is to identify a sex-related difference in Alzheimer’s pathology within this autopsy sample and a question for future studies.
Key Questions
What did the study find?
In 230 autopsy cases of people with Parkinson’s, researchers found higher rates of Alzheimer’s amyloid pathology in women, particularly women with Parkinson’s disease dementia.
Did women also have more tau pathology or greater cognitive impairment?
The researchers reported no difference between women and men in tau pathology or levels of cognitive impairment in the cases they studied.
Does the finding mean women with Parkinson’s have Alzheimer’s disease?
No. The study found more Alzheimer’s-related amyloid pathology in the examined brains. It does not establish that every woman with Parkinson’s has Alzheimer’s disease or that amyloid alone determines a diagnosis.
Could Alzheimer’s drugs treat Parkinson’s disease dementia?
The study did not test treatment. Its authors said the findings could prompt research into anti-amyloid medicines for some patients with Parkinson’s disease dementia who also have increased amyloid pathology. That possibility has not been shown to work and is not a treatment recommendation.
Source: news-medical.net
